

type of report	Current report
number	76/2013
company	PHARMENA

Information on the progress in clinical trials over innovative anti-atherosclerosis medicinal product 1-MNA

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13th April 2012) and the communication on the progress in clinical trials over innovative anti-atherosclerosis medicinal product 1-MNA (published in current report no. 71/2013 of 10th October 2013), the Management Board informs that on 4th November 2013, tablets intended for patients participating in phase II clinical trials over the anti-atherosclerosis medicinal product 1-MNA were delivered to distribution centre. They will be then directed to clinics, which take part in the studies. Recruitment process for patients to be included in clinical trials over 1-MNA medicinal product is planned for mid-November 2013.

The aim of the phase II clinical trial over the 1-MNA anti-atherosclerosis medicinal product will consist in establishing the effective dose of the medicinal product and confirming the lack of side effects in humans in the tested doses. Planned time scope for the trial is 12 months from the date of obtaining permission from Health Canada market regulator (7th October 2013). The supervisory institution will be Montreal Heart Institute, and participation of ca. 15 clinics in the trial is planned.

Montreal Heart Institute is a leading research centre in Canada, specialising in cardiology, and one of the largest institutes of this type in the world. It is a world renown Institute, that has introduced many innovatory solutions nationally and world-wide. For more information, see www.icm-mhi.org.

Phase II clinical trial ("Proof of Concept") is planned to be financed from funds raised in issue of series D shares. Subsequent current reports issued by the Company will inform on progress of research and trials of the 1-MNA innovative anti-atherosclerotic medicinal product.

This information is made public due to the fact that conducting phase II clinical trial is necessary for commercialisation of 1-MNA anti-atherosclerotic medicinal product project, while potential revenues on the medicinal product commercialisation may have very significant impact on financial results and market valuation of the Issuer.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1)".

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wiczorkowska – Vice President of the Board